Baystreet.ca - NeuroSense Gains on Retrospective

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a company developing treatments for severe neurodegenerative diseases, shares a review of important clinical achievements in 2023 and provides a road map for anticipated catalysts in 2024.

Top-line results ...

Related Keywords

, Jeffrey Rosenfeld , Neurosense Therapeutics Ltd , Nasdaq , Neurosense Therapeutics , Scientific Advisory Board ,